Skip to main content
    L

    Ligand Pharmaceuticals Incorporated (LGND)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $301.71
    -7.08 (-2.29%)

    Market Cap: $6.18B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ligand Pharmaceuticals Incorporated (LGND) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    Ligand Pharmaceuticals reported revenue of $268.09M for the fiscal year ended Dec 31, 2025, up 60.4% from the year before. That year, net income was $124.45M with a net margin of 46.4%, operating cash flow was $49.36M and free cash flow was $48.91M. The quarter ended Sep 30, 2026 had revenue of $78.75M and net income of -$28.48M.

    Revenue and Margins

    The operating margin was 15.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $108.97M, a compound annual rate of 10.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$268.09M+60.4%94.6%15.3%46.4%
    Dec 2024$167.13M+27.3%93.4%-13.5%-2.4%
    Dec 2023$131.31M-33.1%92.0%9.1%39.7%
    Dec 2022$196.25M-18.8%73.1%1.5%-17.0%
    Dec 2021$241.54M+47.7%74.3%43.0%23.7%
    Dec 2020$163.56M+36.0%81.4%22.9%-1.8%
    Dec 2019$120.28M-52.2%100.0%671.0%523.2%
    Dec 2018$251.45M+78.2%97.5%65.1%57.0%
    Dec 2017$141.10M+29.5%100.0%48.2%8.9%
    Dec 2016$108.97MN/A94.9%40.3%-1.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$268.09M$167.13M$131.31M$196.25M$241.54M$163.56M$120.28M$251.45M$141.10M$108.97M
    Cost of revenue$14.55M$11.07M$10.51M$52.83M$62.18M$30.42M$0$6.34M$0$5.57M
    Gross profit$253.54M$156.06M$120.80M$143.42M$179.37M$133.14M$120.28M$245.12M$141.10M$103.40M
    Research and development$81.18M$21.43M$24.54M$36.08M$32.10M$40.50M$55.91M$27.86M$26.89M$21.22M
    Operating income$41.00M-$22.61M$11.94M$3.04M$103.85M$37.50M$807.08M$163.73M$68.08M$43.88M
    Net income$124.45M-$4.03M$52.15M-$33.36M$57.14M-$2.98M$629.30M$143.32M$12.56M-$1.64M
    EBITDA$163.62MN/A$49.54M$65.03M$168.79M$91.69M$866.35M$238.30M$93.17MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$78.75M$63.69M$51.72M$59.67M$115.46M$47.63M$45.33M$42.81M$51.81M$41.53M$30.98M$28.10M
    Gross profit$76.10M$60.48M$48.45M$56.67M$111.66M$44.72M$40.48M$39.98M$49.36M$38.63M$28.10M$19.26M
    Operating income-$15.76M$8.59M$17.37M$13.84M$55.39M$8.44M-$36.22M-$9.64M$3.14M-$19.10M$2.99M-$3.36M
    Net income-$28.48M$48.51M-$13.35M$44.78M$117.27M$4.85M-$42.45M-$31.09M-$7.17M-$51.91M$86.14M$18.19M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $446.19M exceeded cash and equivalents by $271.26M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.56B$941.77M$787.22M$762.67M$1.30B$1.36B$1.49B$1.26B$671.02M$601.59M
    Current assets$832.27M$331.56M$237.43M$263.60M$464.75M$500.56M$1.12B$870.54M$237.02M$163.05M
    Cash and equivalents$174.93M$72.31M$22.95M$45.01M$19.52M$47.62M$71.54M$117.16M$20.62M$18.75M
    Total liabilities$543.42M$111.33M$86.30M$165.18M$476.43M$652.76M$727.68M$699.89M$252.37M$230.73M
    Short-term debt$0$1.29M$410.00K$76.69M$0$8.48M$1.25M$26.43M$224.53M$212.91M
    Long-term debt$446.19M$0N/AN/A$320.72M$442.29M$638.96M$609.86M$0$29.56M
    Shareholder equity$1.02B$830.44M$700.91M$597.49M$821.16M$709.52M$767.23M$560.91M$399.79M$341.29M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$2.24B$2.19B$1.53B$1.56B$1.48B$948.60M$905.43M$941.77M$954.87M$866.40M$913.87M$787.22M
    Total liabilities$1.28B$1.22B$534.78M$543.42M$526.60M$120.08M$109.90M$111.33M$113.69M$91.21M$107.35M$86.30M
    Cash and equivalents$55.96M$1.01B$115.08M$174.93M$139.38M$67.67M$47.99M$72.31M$63.62M$18.14M$50.09M$22.95M
    Shareholder equity$961.76M$967.52M$997.32M$1.02B$950.17M$828.53M$795.53M$830.44M$841.18M$775.20M$806.52M$700.91M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 99.1% of operating cash flow. Share repurchases came to 30.7% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$49.36M$97.05M$49.58M$137.85M$78.80M$54.59M-$29.34M$194.06M$88.57M$60.73M
    Capital expenditures$452.00K$76.82M$3.52M$17.92M$8.76M$4.46M$2.55M$887.00K$2.16M$1.85M
    Free cash flow$48.91M$20.23M$46.06M$119.93M$70.04M$50.13M-$31.89M$193.17M$86.41M$58.88M
    Dividends paidN/AN/AN/A$6.80M$0$0$3.00MN/A$0$0
    Share repurchases$15.00M$0$0N/A$18.45M$78.00M$453.43M$152.96M$1.97M$3.90M
    Investing cash flow-$377.32M-$143.66M-$11.68M$163.62M$30.52M$231.65M$466.92M-$423.27M-$79.18M-$134.41M
    Financing cash flow$428.22M$97.14M-$59.95M-$275.99M-$137.76M-$310.55M-$485.17M$328.58M-$7.52M-$4.99M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$27.59M$24.02M$48.69M$45.91M$13.09M$15.80M-$25.45M$28.47M$36.53M$13.31M$18.73M$8.06M
    Capital expenditures$142.00K$26.00K$228.00K$9.00K$15.00K$214.00K$214.00K$712.00K$596.00K$75.41M$105.00K$417.00K
    Free cash flow-$27.73M$23.99M$48.46M$45.91M$13.07M$15.59M-$25.66M$27.76M$35.93M-$62.09M$18.63M$7.65M
    Last 12 quarters

    Frequently Asked Questions About LGND

    What is Ligand Pharmaceuticals' annual revenue?

    Ligand Pharmaceuticals reported revenue of $268.09M for the fiscal year ended Dec 31, 2025.

    How fast is Ligand Pharmaceuticals' revenue growing?

    Revenue was up 60.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 11.0%.

    Is Ligand Pharmaceuticals profitable?

    Yes. Ligand Pharmaceuticals reported net income of $124.45M for the fiscal year ended Dec 31, 2025, with a net margin of 46.4%.

    How much free cash flow does LGND generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $49.36M minus capital expenditures of $452.00K produced free cash flow of $48.91M.

    How much debt does Ligand Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $446.19M, short-term debt of $0 and cash and equivalents of $174.93M.